Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stryker Corporation (NYSE: SYK) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that describe Stryker’s financial condition, governance and material events as a global medical technologies company focused on MedSurg, Neurotechnology and Orthopaedics.
Current reports (Form 8-K) play a central role in Stryker’s disclosure practices. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter 2025 operating results, detailing net sales, segment performance and earnings metrics. Another Form 8-K dated December 4, 2025 reports leadership changes, including the appointment of a President and Chief Operating Officer and a new Group President, Orthopaedics, and summarizes related compensation arrangements.
Through its SEC filings, Stryker also identifies its registered securities and capital structure. Filings list the company’s common stock, traded on the New York Stock Exchange under the symbol SYK, along with multiple series of senior unsecured notes with different maturities that are also listed on the NYSE. These disclosures help investors understand the instruments available for investing in Stryker and the company’s obligations under its notes.
On Stock Titan, Stryker’s filings are updated in step with new submissions to the SEC’s EDGAR system. AI-powered tools summarize key points from lengthy documents, helping readers quickly identify items such as results of operations, leadership changes, segment commentary and descriptions of registered securities. Users can review Stryker’s historical and recent filings to track how the company reports on its MedSurg, Neurotechnology and Orthopaedics businesses, financial performance and governance over time.
Stryker Corporation director Andrew K. Silvernail reported equity transactions in the company’s stock. On January 15, 2026, he exercised a stock option for 4,570 shares of common stock at a price of $96.64 per share, granted under the Stryker Corporation 2011 Long-Term Incentive Plan, which vested in 20% increments over five years.
On the same date, he also disposed of 1,229 shares of common stock at a price of $359.39 per share, as reflected by transaction code “F” in the non-derivative table. Following these transactions, Silvernail directly owned 17,703 shares of Stryker common stock.
Stryker Corp director Ronda E. Stryker reported exercising a stock option and acquiring additional common shares. On 01/14/2026 she exercised a stock option granted on 02/10/2016 for 4,570 shares of common stock at an exercise price of $96.64 per share. Following this transaction, she directly owned 5,783 shares of Stryker common stock.
The filing also lists significant indirect holdings of Stryker common stock. These include 13,578,805 shares held by the L. Lee Stryker Trust, 37,600 shares held by the 1988 William D. Johnston Trust, and 2,702,108 shares held by a Revocable Trust. The stock option was originally granted under the Stryker Corporation 2011 Long-Term Incentive Plan and became exercisable in 20% increments on each of the first five anniversaries of the grant date.
Stryker Corporation Group President Dylan Bram Crotty filed an initial ownership report detailing his equity holdings in SYK. As of 01/01/2026, he reports direct ownership of 5,842 shares of Stryker common stock, plus indirect holdings of 1,480 shares through a 401(k) plan and additional shares held via a personal trust and accounts for his daughter and son.
Crotty also reports a series of employee stock options granted between 2017 and 2025, covering thousands of shares at exercise prices ranging from $122.51 to $392.39 per share. Earlier grants are fully vested, while more recent grants become exercisable in 20% increments on each of the first five anniversaries of the grant date under Stryker’s 2011 Long-Term Incentive Plan.
Stryker Corporation officer M Kathryn Fink reported a tax-related stock transaction. On 12/16/2025, 37 unvested restricted stock units were withheld at a price of $355.31 per share to pay taxes associated with the reporting person becoming retirement eligible.
After this withholding, the reporting person beneficially owned 13,331 shares of Stryker common stock directly, 421 shares through a 401(k), and 177 shares through the 2023 Mary Fink Living Trust. The directly held amount includes 128 shares of Stryker common stock acquired pursuant to Stryker Corporation's Employee Stock Purchase Plan as of September 30, 2025.
Stryker Corp officer William E. Berry, Jr., the company’s VP, Chief Accounting Officer, reported a small tax-related equity transaction involving his Stryker holdings. On 12/16/2025, a Form 4 shows a disposition coded “F” of 28 shares of common stock at a price of $355.31 per share.
The explanation states that 28 unvested restricted stock units (RSUs) from a February 5, 2025 grant of 733 RSUs were withheld to pay taxes associated with the reporting person becoming retirement eligible. After this transaction, he beneficially owns 2,805 shares of Stryker common stock directly and 613 shares indirectly through a 401(k) plan.
Stryker Corporation announced a leadership transition effective January 1, 2026. Spencer Stiles, currently Group President, Orthopaedics, will become President and Chief Operating Officer. Dylan Crotty, currently President, Instruments, will be promoted to Group President, Orthopaedics.
Both executives have 27-year careers at Stryker with leadership roles across Orthopaedics, MedSurg and Neurotechnology, Trauma & Extremities and international regions. Under a letter agreement, Mr. Stiles’s annual base salary will increase to $1,000,000 with a bonus target equal to 100% of salary and a recommended long-term incentive grant with a target value of about $6,000,000, split between stock options and performance stock units, subject to committee approval. Mr. Crotty’s base salary will rise to $700,000 with an 85% bonus target and a recommended long-term incentive grant of about $3,000,000 on similar terms.
Stryker Corp (SYK) Group President James Andrew Pierce reported a family gift of company stock. On 11/21/2025, he transferred 211 shares of common stock from his direct holdings as a gift, reducing his directly held position to 65,630 shares. The gifted shares were split between his two sons, resulting in 712 shares held indirectly through one son and 713 shares held indirectly through the other son.
He also reports an additional 1,591 shares held indirectly through a 401(k) plan. The filing notes that he disclaims beneficial ownership of the shares held by his sons, despite them sharing his household, and states that the report should not be taken as an admission of beneficial ownership for regulatory purposes.
Stryker Corp (SYK) reported an insider stock transaction by its Vice President and Chief Financial Officer. On 11/20/2025, the officer sold 165 shares of Stryker common stock at a price of $365.88 per share, coded as a sale transaction. After this trade, the officer beneficially owned 6,694 shares of common stock directly and an additional 287 shares indirectly through a 401(k) plan. The filing indicates it was submitted by an attorney-in-fact on behalf of the reporting person.
Stryker Corp has a Form 144 notice indicating a planned sale of 165 shares of common stock through UBS Financial Services on the NYSE, with an aggregate market value of
The shares to be sold were acquired on
Stryker Corporation officer William E. Berry, Jr., the VP and Chief Accounting Officer, reported several transactions in company stock. On 11/14/2025, he exercised an employee stock option to buy 4,925 shares of common stock at an exercise price of $154.14 per share under the 2011 Long-Term Incentive Plan. On the same date, 2,972 shares were disposed of in a transaction coded “F,” indicating shares withheld to cover taxes at $373.42 per share, and 1,953 shares were sold in an open market transaction coded “S” at $365.49 per share. After these transactions, he directly owned 2,833 shares of Stryker common stock and indirectly owned 613 shares through a 401(k) plan.